The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-15 and is reviewed periodically as new material appears.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
In order to determine the composition of the East German representatives in the Bundestag between German reunification and the first post-reunification elections in December 1990, the results of the 1990 Volkskammer election were recounted, using the new states of Germany as constituencies. This was possible since the original election results were declared on the Kreis level, and the states were re-established by simply amalgamating Kreise together. The results in each Kreis forming a state were summed up to determine the statewide result. The recount fixed the number of Volkskammer members from each party who would be co-opted into the Bundestag.
This increased demand is met by an increase in the stroke volume of the octopus' heart. The octopus does sometimes swim throughout the water, exposing itself completely. In doing so, it uses a jet mechanism that involves creating a much higher pressure in its mantle cavity that allows it to propel itself through the water. As the common octopus' heart and gills are located within its mantle, this high pressure also constricts and puts constraints on the various vessels that are returning blood to the heart. Ultimately, this creates circulation issues and is not a sustainable form of transportation, as the octopus cannot attain an oxygen intake that can balance the metabolic demands of maximum exertion.
The TV show Inside Amy Schumer premiered on Comedy Central on April 30, 2013. Inside Amy Schumer was picked up for a second season that began in 2014. A behind-the-scenes miniseries entitled Behind Amy Schumer premiered in 2012. The third season premiered on April 21, 2015, with a fourth season ordered the same day. In 2014, Schumer embarked on her Back Door Tour to promote the second season of her show. The show was closed by Bridget Everett, whom Schumer cites as her favorite live performer. She also appeared as a guest on an episode of comedian Jerry Seinfeld's Internet series Comedians in Cars Getting Coffee in 2014. She hosted the 2015 MTV Movie Awards, which took place on April 11. Schumer wrote and played her first leading film role in Trainwreck, co-starring Bill Hader, which was released on July 17, 2015. In August 2015, Jennifer Lawrence said she and Schumer planned to co-star in a film for which they and Schumer's sister Kim were co-writing a screenplay. However, Schumer later revealed the project was on the "back burner". Schumer performed as opening act for Madonna on three New York City dates of the singer's Rebel Heart Tour in September 2015. On October 17, 2015, Schumer's comedy special Amy Schumer: Live at the Apollo premiered on HBO. In 2016, it was nominated for three Primetime Emmy Awards for Outstanding Variety Special, Writing, and Directing. It also garnered her a nomination for the Grammy Award for Best Comedy Album. Schumer started her first world tour on August 26 in Dublin.
=== Breast cancer === Anastrozole is used in the treatment and prevention of breast cancer in women. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was of localized breast cancer and women received either anastrozole, the selective estrogen receptor modulator tamoxifen, or both for five years, followed by five years of follow-up. After more than 5 years the group that received anastrozole had better results than the tamoxifen group. The trial suggested that anastrozole is the preferred medical therapy for postmenopausal women with localized estrogen receptor-positive breast cancer.
== Form and appearance == Heinz bodies appear as small round inclusions within the red cell body, though they are not visible when stained with Romanowsky dyes. They are visualized more clearly with supravital staining (e.g., with new methylene blue, crystal violet or bromocresol green).
Sources: en.wikipedia.org
yr, but in the past 40 years, the experimental scene has been dominated by the KamiokaNDE experiment and its successor Super-Kamiokande. The construction of KamiokaNDE experiment under the direction of Masatoshi Koshiba was completed in 1983. The detector was a cylindrical tank (16 m in height and 15.6 m in diameter) containing 3,000 tons of pure water, equipped with about 1,000 photomultiplier tubes (PMTs) arranged on the lateral surface. It was located in the Kamioka zinc mine (near the city of Hida, Gifu Prefecture, Japan). The photomultipliers detected Cherenkov light, emitted by charged particles traversing the water at speeds greater than the speed of light in the medium. KamiokaNDE was able to set stringent lower limits on the proton lifetime (
Vaginal estradiol is available in the forms of tablets, creams, inserts or suppositories, and rings. Vaginal estradiol tablets, creams, and inserts are usually administered once daily to twice weekly, whereas vaginal estradiol rings have a sustained action and are replaced once every 90 days. Vaginal estradiol can be used both as a systemic form of estradiol therapy, and at very low doses to selectively achieve a local vaginal effect without systemic effects, for instance in the treatment of menopausal symptoms such as vaginal atrophy and dryness. Vaginal estradiol is rapidly and almost completely absorbed. The absorption of vaginal estradiol is slightly greater in women with vaginal atrophy. Vaginal estradiol has high bioavailability and greatly increased potency compared to oral estradiol, with about 10- to 20-fold the comparative potency of oral estradiol. The greater potency of vaginal estradiol relative to oral estradiol is due to the lack of the first pass associated with oral estradiol and due to low local metabolism of estradiol in the vagina. Because of the high estradiol levels achieved, LH and FSH are more strongly suppressed with vaginal estradiol than with other routes. A daily dosage of 0.5 mg vaginal micronized estradiol has been found to result in estradiol and estrone levels of 250 pg/mL and 130 pg/mL, respectively. Vaginal estradiol has a much higher estradiol-to-estrone ratio in comparison to oral estradiol. The average ratio of estradiol to estrone with vaginal estradiol is 5:1, compared to 1:5 in the case of oral estradiol, a 10-fold difference.
==== 5α-DHP subpathway ==== The pathway from progesterone (P4) to DHT is similar to that described above from 17OHP to DHT, but the initial substrate for 5α-reductase is P4 rather than 17OHP. Placental P4 in the male fetus is the feedstock, that is, a starting point, the initial substrate, for the backdoor pathway found operating in multiple non-gonadal tissues. The first step in this pathway is 5α-reduction of P4 toward 5α-dihydroprogesterone (5α-DHP) by SRD5A1. 5α-DHP is then converted to allopregnanolone (AlloP5) via 3α-reduction by AKR1C2 or AKR1C4. AlloP5 is then converted to 5α-Pdiol by the 17α-hydroxylase activity of CYP17A1. 5α-Pdiol is also known as 17α-hydroxyallopregnanolone or 17OH-allopregnanolone. 5α-Pdiol is then converted to 5α-androstan-3α-ol-17-one, also known as androsterone (AST) by 17,20-lyase activity of CYP17A1 which cleaves a side-chain (C17-C20 bond) from the steroid nucleus, converting a C21 steroid (a pregnane) to a C19 steroid (an androstane or androgen). AST is 17β-reduced to 5α-androstane-3α,17β-diol (3α-diol) by HSD17B3 or AKR1C3. The final step is 3α-oxidation of 3α-diol in target tissues to DHT by an enzyme that has 3α-hydroxysteroid oxidase activity, such as AKR1C2, HSD17B6, HSD17B10, RDH16, RDH5, and DHRS9. This oxidation is not required in the classical androgen pathway. The pathway can be summarized as: P4 → 5α-DHP → AlloP5 → 5α-Pdiol → AST → 3α-diol → DHT.
=== Alternative medicine === Honey has been used since ancient times to aid wound healing and may be beneficial in first- and second-degree burns. There is moderate evidence that honey helps heal partial thickness burns. The evidence for aloe vera is of poor quality. While it might be beneficial in reducing pain, and a review from 2007 found tentative evidence of improved healing times, a subsequent review from 2012 did not find improved healing over silver sulfadiazine. A 2014 review found only three randomized controlled trials for the use of plants for burns, two for aloe vera and one for oatmeal. The number of randomized control trials for aloe vera had increased to nine by 2024, when a review found a significant improvement in healing time but not pain relief. There is little evidence that vitamin E helps with keloids or scarring. Butter is not recommended. In low income countries, burns are treated up to one-third of the time with traditional medicine, which may include applications of eggs, mud, leaves or cow dung. Surgical management is limited in some cases due to insufficient financial resources and availability. There are a number of other methods that may be used in addition to medications to reduce procedural pain and anxiety including virtual reality therapy, hypnosis, and behavioral approaches such as distraction techniques.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.